Treatment of Acute Myeloid Leukemia in the Community Setting

TL;DR

This paper summarizes a discussion on treating acute myeloid leukemia in community hospitals, focusing on new therapies and challenges.

Contribution

The paper provides insights from a symposium on implementing new AML treatments in community oncology settings.

Findings

New agents and lower-intensity regimens for AML are being used in community settings.

The FDA and experts discussed challenges and opportunities in community-based AML treatment.

Abstract

The treatment landscape for acute myeloid leukemia (AML) is rapidly changing. Many new agents and lower-intensity regimens have been approved and can be safely used by hematologists and oncologists in both academic and community settings. The US Food and Drug Administration (FDA) held a virtual symposium on AML treatment in the community in November 2022. Several members of the FDA, along with practicing hematologists and oncologists in both academic and community settings, participated in the symposium. The goal of the symposium was to discuss challenges and opportunities in the treatment of patients with AML in community oncology settings. A summary of these discussions and key considerations are presented here.

The FDA held a virtual symposium on acute myeloid leukemia (AML) treatment in the community in November 2022 to discuss challenges and opportunities in the treatment of patients with AML in community oncology settings. A summary of these discussions and key considerations are presented here.

Figures